The Molecular Mechanisms Study of Engeletin Suppresses RANKL-Induced Osteoclastogenesis and Inhibits Ovariectomized Murine Model Bone Loss

References

• Cummings SR. Lifetime risks of hip, colles’, or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med. 1989;149(11):2445–2448.
   PubMedGoogle Scholar
• Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137–1141. doi:10.1002/jbmr.5650090802
   PubMed Web of Science ®Google Scholar
• Lane JM, Russell L, Khan SN. Osteoporosis. Clin Orthop Relat Res. 2000;372:139–150. doi:10.1097/00003086-200003000-00016
   Google Scholar
• Srivastava M, Deal C. Osteoporosis in elderly: prevention and treatment. Clin Geriatr Med. 2002;18:529–555. doi:10.1016/S0749-0690(02)00022-8
   PubMed Web of Science ®Google Scholar
• Chen B, Meinertzhagen IA, Shaw SR. Circadian rhythms in light-evoked responses of the fly’s compound eye, and the effects of neuromodulators 5-HT and the peptide. J Comp Physiol A. 1999;185:393–404. doi:10.1007/s003590050400
   PubMed Web of Science ®Google Scholar
• Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377:1276–1287. doi:10.1016/S0140-6736(10)62349-5
   PubMed Web of Science ®Google Scholar
• Parfitt AM. Bone remodeling and bone loss: understanding the pathophysiology of osteoporosis. Clin Obstet Gynecol. 1987;30:789–811. doi:10.1097/00003081-198712000-00004
   PubMed Web of Science ®Google Scholar
• Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: t cells, bone loss, and mammalian evolution. Annu Rev Immunol. 2002;20:795–823. doi:10.1146/annurev.immunol.20.100301.064753
   PubMed Web of Science ®Google Scholar
• Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337–342. doi:10.1038/nature01658
   PubMed Web of Science ®Google Scholar
• Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone. 2007;40:251–264. doi:10.1016/j.bone.2006.09.023
   PubMed Web of Science ®Google Scholar
• Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science. 2000;289:1501–1504. doi:10.1126/science.289.5484.1501
   PubMed Web of Science ®Google Scholar
• Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289:1504–1508. doi:10.1126/science.289.5484.1504
   PubMed Web of Science ®Google Scholar
• Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175–179. doi:10.1038/36593
   PubMed Web of Science ®Google Scholar
• Wong BR, Rho J, Arron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem. 1997;272:25190–25194. doi:10.1074/jbc.272.40.25190
   PubMed Web of Science ®Google Scholar
• Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998;139:1329–1337. doi:10.1210/endo.139.3.5837
   PubMed Web of Science ®Google Scholar
• Lomaga MA, Yeh WC, Sarosi I, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 1999;13:1015–1024. doi:10.1101/gad.13.8.1015
   PubMed Web of Science ®Google Scholar
• Ha H, Kwak HB, Lee SW, et al. Reactive oxygen species mediate RANK signaling in osteoclasts. Exp Cell Res. 2004;301:119–127. doi:10.1016/j.yexcr.2004.07.035
   PubMed Web of Science ®Google Scholar
• Yip KH, Zheng MH, Steer JH, et al. Thapsigargin modulates osteoclastogenesis through the regulation of RANKL-induced signaling pathways and reactive oxygen species production. J Bone Miner Res. 2005;20:1462–1471. doi:10.1359/JBMR.050324
   PubMed Web of Science ®Google Scholar
• Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006;12:17–25. doi:10.1016/j.molmed.2005.11.007
   PubMed Web of Science ®Google Scholar
• Tewtrakul S, Itharat A, Rattanasuwan P. Anti-HIV-1 protease- and HIV-1 integrase activities of Thai medicinal plants known as Hua-Khao-Yen. J Ethnopharmacol. 2006;105:312–315. doi:10.1016/j.jep.2005.11.021
   PubMed Web of Science ®Google Scholar
• She T, Zhao C, Feng J, et al. Sarsaparilla (Smilax Glabra Rhizome) extract inhibits migration and invasion of cancer cells by suppressing TGF-β1 pathway. PLoS One. 2015;10:e0118287. doi:10.1371/journal.pone.0118287
   PubMed Web of Science ®Google Scholar
• Wang C, La L, Feng H, et al. Aldose reductase inhibitor engeletin suppresses pelvic inflammatory disease by blocking the phospholipase C/Protein Kinase C-Dependent/NF-κB and MAPK Cascades. J Agric Food Chem. 2020;68:11747–11757. doi:10.1021/acs.jafc.0c05102
   PubMed Web of Science ®Google Scholar
• Zhao JW, Zheng CY, Wei H, Wang DW, Zhu W. Proapoptic and immunotoxic effects of sulfur-fumigated polysaccharides from Smilax glabra Roxb. in RAW264.7 cells. Chem Biol Interact. 2018;292:84–93. doi:10.1016/j.cbi.2018.07.009
   PubMed Web of Science ®Google Scholar
• Wang H, Jiang Z, Pang Z, et al. Engeletin protects against TNF-α-induced apoptosis and reactive oxygen species generation in chondrocytes and alleviates osteoarthritis in vivo. J Inflamm Res. 2021;14:745–760. doi:10.2147/JIR.S297166
   PubMed Web of Science ®Google Scholar
• Zhao X, Chen R, Shi Y, Zhang X, Tian C, Xia D. Antioxidant and anti-inflammatory activities of six flavonoids from smilax glabra Roxb. Molecules. 2020;25:5295. doi:10.3390/molecules25225295
   PubMed Web of Science ®Google Scholar
• Liu T, Li Y, Sun J, Tian G, Shi Z. Engeletin suppresses lung cancer progression by inducing apoptotic cell death through modulating the XIAP signaling pathway: a molecular mechanism involving ER stress. Bio Pharmacot. 2020;128:110221. doi:10.1016/j.biopha.2020.110221
   Google Scholar
• Cai Y, Tu J, Pan S, et al. Medicinal effect and its JP2/RyR2-based mechanism of Smilax glabra flavonoids on angiotensin II-induced hypertrophy model of cardiomyocytes. J Ethnopharmacol. 2015;169:435–440. doi:10.1016/j.jep.2015.04.026
   PubMed Web of Science ®Google Scholar
• Plotkin LI, Bellido T. Osteocytic signalling pathways as therapeutic targets for bone fragility. Nat Rev Endocrinol. 2016;12:593–605. doi:10.1038/nrendo.2016.71
   PubMed Web of Science ®Google Scholar
• Udagawa N, Koide M, Nakamura M, et al. Osteoclast differentiation by RANKL and OPG signaling pathways. J Bone Miner Metab. 2021;39:19–26. doi:10.1007/s00774-020-01162-6
   PubMed Web of Science ®Google Scholar
• Qu Z, Zhang B, Kong L, et al. Receptor activator of nuclear factor-κB ligand-mediated osteoclastogenesis signaling pathway and related therapeutic natural compounds. Front Pharmacol. 2022;13:1043975. doi:10.3389/fphar.2022.1043975
   PubMed Web of Science ®Google Scholar
• Søe K, Delaisse JM, Borggaard XG. Osteoclast formation at the bone marrow/bone surface interface: importance of structural elements, matrix, and intercellular communication. Semin Cell Dev Biol. 2021;112:8–15. doi:10.1016/j.semcdb.2020.05.016
   PubMed Web of Science ®Google Scholar
• Kong L, Smith W, Hao D. Overview of RAW264.7 for osteoclastogensis study: phenotype and stimuli. J Cell Mol Med. 2019;23:3077–3087. doi:10.1111/jcmm.14277
   PubMed Web of Science ®Google Scholar
• Yasuda H. Discovery of the RANKL/RANK/OPG system. J Bone Miner Metab. 2021;39:2–11. doi:10.1007/s00774-020-01175-1
   PubMed Web of Science ®Google Scholar
• Ono T, Hayashi M, Sasaki F, Nakashima T. RANKL biology: bone metabolism, the immune system, and beyond. Inflamm Regen. 2020;40:2. doi:10.1186/s41232-019-0111-3
   PubMed Web of Science ®Google Scholar
• Elango J, Bao B, Wu W. The hidden secrets of soluble RANKL in bone biology. Cytokine. 2021;144:155559. doi:10.1016/j.cyto.2021.155559
   PubMed Web of Science ®Google Scholar
• Mognol GP, González-Avalos E, Ghosh S, et al. Targeting the NFAT:AP-1 transcriptional complex on DNA with a small-molecule inhibitor. Proc Natl Acad Sci U S A. 2019;116:9959–9968. doi:10.1073/pnas.1820604116
   PubMed Web of Science ®Google Scholar
• Fleischmann A, Hafezi F, Elliott C, Remé CE, Rüther U, Wagner EF. Fra-1 replaces c-Fos-dependent functions in mice. Genes Dev. 2000;14:2695–2700. doi:10.1101/gad.187900
   PubMed Web of Science ®Google Scholar
• Zhao Q, Wang X, Liu Y, He A, Jia R. NFATc1: functions in osteoclasts. Int J Biochem Cell Biol. 2010;42:576–579. doi:10.1016/j.biocel.2009.12.018
   PubMed Web of Science ®Google Scholar
• Wagner EF, Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol Rev. 2005;208:126–140. doi:10.1111/j.0105-2896.2005.00332.x
   PubMed Web of Science ®Google Scholar
• Yang D, Wan Y. Molecular determinants for the polarization of macrophage and osteoclast. Semin Immunopathol. 2019;41:551–563. doi:10.1007/s00281-019-00754-3
   PubMed Web of Science ®Google Scholar
• Lin B, Ke Q, Leaman DW, Goel V, Agarwal A. Regulation of RANKL-induced osteoclastogenesis by RING finger protein RNF114. J Orthop Res. 2018;36:159–166. doi:10.1002/jor.23654
   PubMed Web of Science ®Google Scholar
• Guo J, Ren R, Sun K, et al. PERK controls bone homeostasis through the regulation of osteoclast differentiation and function. Cell Death Dis. 2020;11:847. doi:10.1038/s41419-020-03046-z
   PubMed Web of Science ®Google Scholar
• Lee K, Chung YH, Ahn H, Kim H, Rho J, Jeong D. Selective Regulation of MAPK signaling mediates RANKL-dependent osteoclast differentiation. Int J Biol Sci. 2016;12:235–245. doi:10.7150/ijbs.13814
   PubMed Web of Science ®Google Scholar
• Thouverey C, Caverzasio J. Focus on the p38 MAPK signaling pathway in bone development and maintenance. Bonekey Rep. 2015;4:711. doi:10.1038/bonekey.2015.80
   PubMedGoogle Scholar
• Koga Y, Tsurumaki H, Aoki-Saito H, et al. Roles of Cyclic AMP response element binding activation in the ERK1/2 and p38 MAPK signalling pathway in central nervous system, cardiovascular system, osteoclast differentiation and mucin and cytokine production. Int J Mol Sci. 2019;20:1346. doi:10.3390/ijms20061346
   PubMed Web of Science ®Google Scholar
• Agidigbi TS, Kim C. Reactive oxygen species in osteoclast differentiation and possible pharmaceutical targets of ROS-mediated osteoclast diseases. Int J Mol Sci. 2019;20:3576. doi:10.3390/ijms20143576
   PubMed Web of Science ®Google Scholar
• Bellezza I, Giambanco I, Minelli A, Donato R. Nrf2-Keap1 signaling in oxidative and reductive stress. Biochim Biophys Acta Mol Cell Res. 2018;1865:721–733. doi:10.1016/j.bbamcr.2018.02.010
   PubMed Web of Science ®Google Scholar
• Ulasov AV, Rosenkranz AA, Georgiev GP, Sobolev AS. Nrf2/Keap1/ARE signaling: towards specific regulation. Life Sci. 2022;291:120111. doi:10.1016/j.lfs.2021.120111
   PubMed Web of Science ®Google Scholar